Experimental Hematology
Volume 38, Issue 1 , Pages 27-37 , January 2010

Effect of imatinib on the signal transduction cascade regulating telomerase activity in K562 (BCR-ABL–positive) cells sensitive and resistant to imatinib

  • Rahav Mor-Tzuntz

      Affiliations

    • Felsenstein Medical Research Center, Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Petah-Tikva, Israel
    • ,
  • Orit Uziel

      Affiliations

    • Felsenstein Medical Research Center, Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Petah-Tikva, Israel
    • ,
  • Ofer Shpilberg

      Affiliations

    • Felsenstein Medical Research Center, Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Petah-Tikva, Israel
    • Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Petah-Tikva, Israel
    • ,
  • Judith Lahav

      Affiliations

    • Felsenstein Medical Research Center, Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Petah-Tikva, Israel
    • Hematology Laboratory, Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Petah-Tikva, Israel
    • ,
  • Pia Raanani

      Affiliations

    • Felsenstein Medical Research Center, Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Petah-Tikva, Israel
    • Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Petah-Tikva, Israel
    • ,
  • Mary Bakhanashvili

      Affiliations

    • Division of Infectious Diseases, Sheba Medical Center, Tel-Hashomer, Israel
    • ,
  • Esther Rabizadeh

      Affiliations

    • Felsenstein Medical Research Center, Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Petah-Tikva, Israel
    • Hematology Laboratory, Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Petah-Tikva, Israel
    • ,
  • Yael Zimra

      Affiliations

    • Felsenstein Medical Research Center, Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Petah-Tikva, Israel
    • Hematology Laboratory, Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Petah-Tikva, Israel
    • ,
  • Meir Lahav

      Affiliations

    • Felsenstein Medical Research Center, Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Petah-Tikva, Israel
    • Medicine A, Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Petah-Tikva, Israel
    • ,
  • Galit Granot

      Affiliations

    • Felsenstein Medical Research Center, Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Petah-Tikva, Israel
    • Corresponding Author InformationOffprint requests to: Galit Granot, Ph.D., Felsenstein Medical Research Center, Rabin Medical Center, Beilinson Hospital, 39 Jabotinski Street, Petah-Tikva 49100, Israel

Received 2 February 2009 ,Revised 10 September 2009 ,Accepted 14 October 2009.

References 

  1. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7:441–453
  2. Jabbour E, Cortes JE, Giles FJ, O'Brien S, Kantarjian HM. Current and emerging treatment options in chronic myeloid leukemia. Cancer. 2007;109:2171–2181
  3. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet. 2007;370:342–350
  4. Gumireddy K, Baker SJ, Cosenza SC, et al. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci U S A. 2005;102:1992–1997
  5. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876–880
  6. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16:2190–2196
  7. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 2003;101:690–698
  8. Gambacorti-Passerini C, Barni R, le Coutre P, et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst. 2000;92:1641–1650
  9. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 2004;104:3739–3745
  10. Illmer T, Schaich M, Platzbecker U, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia. 2004;18:401–408
  11. Lankat-Buttgereit B, Hörsch D, Barth P, Arnold R, Blöcker S, Göke R. Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumor cell growth. Digestion. 2005;71:131–140
  12. Uziel O, Fenig E, Nordenberg J, et al. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer. 2005;92:1881–1891
  13. Wihlidal P, Karlic H, Pfeilstöcker M, Klaushofer K, Varga F. Imatinib mesylate (IM)-induced growth inhibition is associated with production of spliced osteocalcin-mRNA in cell lines. Leuk Res. 2008;32:437–443
  14. Shay JW, Keith WN. Targeting telomerase for cancer therapeutics. Br J Cancer. 2008;98:677–683
  15. Kim S, Kaminker P, Campisi J. Telomeres, aging and cancer: in search of a happy ending. Oncogene. 2002;21:503–511
  16. Aisner DL, Wright WE, Shay JW. Telomerase regulation: not just flipping the switch. Curr Opin Genet Dev. 2002;12:80–85
  17. Kang SS, Kwon T, Kwon DY, Do SI. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem. 1999;274:13085–13090
  18. Liu JP. Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J. 1999;13:2091–2104
  19. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis. 2004;9:667–676
  20. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997;33:787–791
  21. Tauchi T, Shin-ya K, Sashida G, et al. Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia. Oncogene. 2006;25:5719–5725
  22. Chen SM, Tao ZZ, Hua QQ, et al. Inhibition of telomerase activity in cancer cells using short hairpin RNA expression vectors. Cancer Invest. 2007;25:691–698
  23. Zhou JH, Zhang HM, Chen Q, et al. Relationship between telomerase activity and its subunit expression and inhibitory effect of antisense hTR on pancreatic carcinoma. World J Gastroenterol. 2003;9:1808–1814
  24. Glukhov AI, Zimnik OV, Gordeev SA, Severin SE. Inhibition of telomerase activity of melanoma cells in vitro by antisense oligonucleotides. Biochem Biophys Res Commun. 1998;248:368–371
  25. Villa R, Folini M, Porta CD, et al. Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells. Carcinogenesis. 2003;24:851–859
  26. Drucker L, Uziel O, Tohami T, et al. Thalidomide down-regulates transcript levels of GC-rich promoter genes in multiple myeloma. Mol Pharmacol. 2003;64:415–420
  27. Phatak P, Burger AM. Telomerase and its potential for therapeutic intervention. Br J Pharmacol. 2007;152:1003–1011
  28. Campbell LJ, Fidler C, Eagleton H, et al. hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia. Leukemia. 2006;20:671–679
  29. Brummendorf TH, Ersoz I, Hartmann U, et al. Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemia. Ann N Y Acad Sci. 2003;996:26–38
  30. Tauchi T, Nakajima A, Sashida G, et al. Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells. Clin Cancer Res. 2002;8:3341–3347
  31. Hartmann U, Balabanov S, Ziegler P, et al. Telomere length and telomerase activity in the BCR-ABL-transformed murine Pro-B cell line BaF3 is unaffected by treatment with imatinib. Exp Hematol. 2005;33:542–549
  32. Bakhanashvili M, Hizi A. Fidelity of the reverse transcriptase of human immunodeficiency virus type 2. FEBS Lett. 1992;306:151–156
  33. Zhu X, Kumar R, Mandal M, et al. Cell cycle-dependent modulation of telomerase activity in tumor cells. Proc Natl Acad Sci U S A. 1996;93:6091–6095
  34. Dan S, Naito M, Tsuruo T. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR - ABL tyrosine kinase, CGP 57148. Cell Death Differ. 1998;5:710–715
  35. Opitz OG. Telomeres, telomerase and malignant transformation. Curr Mol Med. 2005;5:219–226
  36. Yang Y, Chen Y, Zhang C, Huang H, Weissman SM. Nucleolar localization of HTERT protein is associated with telomerase function. Exp Cell Res. 2002;277:201–209
  37. Kharbanda S, Kumar V, Dhar S, et al. Regulation of the hTERT telomerase catalytic subunit by the c-Abl tyrosine kinase. Curr Biol. 2000;10:568–575
  38. Bakalova R, Ohba H, Zhelev Z, Ishikawa M, Shinohara Y, Baba Y. Cross-talk between Bcr-Abl tyrosine kinase, protein kinase C and telomerase—a potential reason for resistance to Glivec in chronic myelogenous leukaemia. Biochem Pharmacol. 2003;66:1879–1884
  39. Burchert A, Wang Y, Cai D, et al. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia. 2005;19:1774–1782
  40. Kharas MG, Fruman DA. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res. 2005;65:2047–2053
  41. Krugmann S, Cooper MA, Williams DH, Hawkins PT, Stephens LR. Mechanism of the regulation of type IB phosphoinositide 3OH-kinase byG-protein betagamma subunits. Biochem J. 2002;362:725–731
  42. Brock C, Schaefer M, Reusch HP, et al. Roles of G beta gamma in membrane recruitment and activation of p110 gamma/p101 phosphoinositide 3-kinase gamma. J Cell Biol. 2003;160:89–99
  43. Torres J, Rodriguez J, Myers MP, et al. Phosphorylation-regulated cleavage of the tumor suppressor PTEN by caspase-3: implications for the control of protein stability and PTEN-protein interactions. J Biol Chem. 2003;278:30652–30660
  44. Jacquel A, Herrant M, Legros L, et al. Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward the erythroid lineage. FASEB J. 2003;17:2160–2162
  45. Brümmendorf TH, Holyoake TL, Rufer N, et al. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood. 2000;95:1883–1890
  46. Zhang W, Piatyszek MA, Kobayashi T, et al. Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents. Clin Cancer Res. 1996;2:799–803
  47. Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood. 1995;85:2315–2320
  48. Engelhardt M, Mackenzie K, Drullinsky P, Silver RT, Moore MA. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Cancer Res. 2000;60:610–617
  49. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat. 2002;5:234–248
  50. Kawauchi K, Ogasawara T, Yasuyama M, Ohkawa S. Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells. Blood Cells Mol Dis. 2003;31:11–17
  51. Corbacioglu S, Kilic M, Westhoff MA, Reinhardt D, Fulda S, Debatin KM. Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin. Blood. 2006;108:3504–1353

PII: S0301-472X(09)00396-8

doi: 10.1016/j.exphem.2009.10.005

Experimental Hematology
Volume 38, Issue 1 , Pages 27-37 , January 2010

Article Tools

* Image Usage & Resolution